LABORATOIRES GENEVRIER Jeremy Bradshaw Lucie-Anne Henry Roberto J. Hinojosa

Presentation of the company Biotechnological laboratory founded in1920 in Neuilly-sur-Seine, France. 1987: move to the heart of Sophia Antipolis research park to be close with Swiss partner Laboratoires IBSA (Controlling Interest) Operating with state of the art Production unit and Research & Development center Major fields of expertise: Dermatology, Rhumatology, Pneumology, Physical and sport medicine 2006 : MEDEC, Best French laboratory

Presentation of the company 235 employees Turnover ~ 69 Million € in 2003 * 14% to 18% of turnover is dedicated to R&D Customers: (99% of products are prescriptive drugs) –Direct: Health Professional –Indirect: Patients Suppliers: Doctors, Professors, Professional scientists *

Technology portfolio The Laboratoires Genévrier Biotechnology Centre for cell therapy –EPIBASE autologous skin care Creation of a new drug every 18 months The Modes of Tech. Access –In-house R&D –Non-equity R&D Joint Venture

F rom a tiny skin sample (biopsy), EPIBASE®, provides on 85 cm² skin layer available in 3 weeks and is a simple application treatment that helps start the healing process. Keratinocytes are specialist cells in the epidermis. Keratinocytes migrate from the depths of the skin to the surface, filling themselves with a protein: keratin. This protein gives the epidermis its protective properties against the external environment. EPIBASE®: from biopsy to fitting

Contact Thibault Machavoine –Reporting & Purchasing department BP Sophia-Antipolis Cedex 280, rue de Goa. Z.I - Les Trois Moulins Parc de Sophia-Antipolis Antibes Tél. 33 (0) Fax 33 (0)